Astellas Pharma Europe Limited

STAINES, England and SAN DIEGO, California, September 23, 2011 - Astellas Pharma Europe Ltd.

STAINES, England, September 21, 2011 - ThePainWithin, a touring exhibition of portraits and images by award-winning photographer Alex Telfer, reveals the untold stories of some of Europe'speripheral neuropathic pain (PNP) patients "I find it incredibly hard to be a mother with neuropathic pain"…"It feels like I'm being stabbed with a knife over and over again"…"I wasn't able to work, drive my car or participate in family life" is how just three patients describe their experiences of PNP.

STAINES, England, September 21, 2011 - - ThePainWithin, a touring exhibition of portraits and images by award-winning photographer Alex Telfer, reveals the untold stories of some of Europe'speripheral neuropathic pain (PNP) patients "I find it incredibly hard to be a mother with neuropathic pain"…"It feels like I'm being stabbed with a knife over and over again"…"I wasn't able to work, drive my car or participate in family life" is how just three patients describe their experiences of PNP.

STAINES, England, September 21, 2011 - Astellas Pharma Europe Ltd.

STAINES, England, September 5, 2011 - - Optimizing ImmunoSuppression After Kidney Transplantation with ADVAGRAF (OSAKA) study results presented at the European Society for Organ Transplantation 2011 congress - Results show non-inferiority of ADVAGRAF vs PROGRAF at the same daily dose in renal transplantation - Higher starting dose of ADVAGRAF gave no additional efficacy benefits - The overriding factor influencing kidney function after transplantation was donor age The results of one of the largest clinical studies ever conducted in de novo kidney transplant recipients, the 6-month OSAKA study, demonstrate that tacrolimus prolonged release (QD; ADVAGRAF™, Graceptor in Japan)-based therapy is non-inferior to the same initial daily dose of tacrolimus immediate release (BID; PROGRAF™)-based therapy (0.2mg/kg/day) for efficacy in renal transplantation.